What TB-500 is
TB-500 is a synthetic peptide representing a biologically active fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein encoded by the TMSB4X gene and found in virtually every nucleated cell in the body. The fragment corresponds to positions 17-23 of the full-length protein and contains the actin-binding domain considered responsible for most of Tβ4's downstream signaling activity.
Thymosin beta-4 itself plays a well-documented role in actin polymerization, which is fundamental to cell shape, motility, and the wound-healing cascade. When tissue is injured, Tβ4 is upregulated at the site; it promotes the migration of keratinocytes and endothelial cells needed for repair. TB-500, as the isolated active fragment, is studied on the hypothesis that delivering this sequence directly may replicate or amplify those repair signals.
It is worth being precise about what "related to thymosin beta-4" means, because the phrase is used loosely in vendor materials. TB-500 is a truncated synthetic fragment, not thymosin beta-4 itself. The two share a key sequence, but they are different molecules with potentially different pharmacokinetics, stability profiles, and biological activity. Research findings on full-length Tβ4 cannot be assumed to apply directly to the isolated fragment and vice versa.
TB-500 has never been approved for human use in any country.
Unlike some peptides that have a prior approval history or a structural analog with approved status, TB-500 has no regulatory pathway it has passed through. There is no approved drug version of this compound. Full-length thymosin beta-4 has been studied in human trials for specific indications (including wound healing and dry eye disease), but those trials did not involve the isolated TB-500 fragment and did not result in approved products. Research-labeled TB-500 sold today is not backed by a clinical trial package, a completed IND, or any equivalent regulatory review for the human use cases most commonly marketed. Always consult a licensed healthcare provider before making health-related decisions.
How TB-500 is discussed and marketed
Online discussion of TB-500 clusters heavily around injury recovery, soft tissue repair, and performance. Here is how each major area maps against the current research, and where the evidence actually ends.
Wound and soft tissue healing
The most supported area in preclinical research. Rodent and in vitro models show accelerated wound closure, improved skin cell migration, and reduced inflammation following Tβ4 and TB-500 administration. These findings are reproducible in animal models. Whether they translate to meaningful outcomes in humans has not been tested in controlled trials.
Preclinical onlyTendon and ligament repair
Preclinical evidence suggests thymosin beta-4 fragments may promote connective tissue healing by modulating inflammation and supporting cell recruitment. This is the framing most commonly applied to athletic injury use. Controlled human evidence does not exist. The preclinical models involve acute injury contexts that may not reflect chronic or repetitive sports injuries.
Preclinical onlyCardiac repair
Research into Tβ4 in cardiac contexts is one of the more active scientific areas. Animal studies have examined cardiac muscle repair after infarction. A small number of human studies with full-length Tβ4 exist but have not established clinical efficacy. TB-500 specifically has not been studied in human cardiac trials.
Emerging researchNeurological recovery
Preclinical models have explored Tβ4 in traumatic brain injury and spinal cord injury contexts, with signals for reduced inflammation and improved recovery. TB-500-specific studies in this area are sparse. Human evidence does not exist. This is early-stage research extrapolated from mechanistic animal studies.
Early preclinicalThe pattern across all four areas is consistent: the mechanistic rationale is grounded in real biology, and the preclinical signals are interesting enough to have attracted legitimate scientific interest. The jump from those animal and in vitro findings to human outcomes has not been made in controlled research. Most of what circulates in marketing and online communities treats the preclinical literature as if it were clinical evidence. It is not.
One additional consideration worth naming directly: TB-500 is listed on the WADA Prohibited List under S2 (Peptide Hormones, Growth Factors, and Related Substances). The prohibition applies both in-competition and out-of-competition. Athletes governed by any WADA-signatory organization who are considering this compound should understand that "research compound" status does not confer exemption from anti-doping rules. A positive test is a positive test regardless of how the compound was labeled or sourced.
Note on informational context: Some discussions of TB-500 include general reference ranges observed in research settings. Where those appear in scientific literature, they are documented here for informational purposes only. They do not constitute a dosing protocol, and this article does not provide guidance on administration for human use, which would be outside both the compound's regulatory status and the scope of this publication.
How to evaluate a vendor selling TB-500
Because TB-500 exists only as a research compound with no approved pharmaceutical counterpart, quality assurance falls entirely on the vendor's testing practices. There is no regulatory floor that guarantees purity, identity, or potency. A vendor's certificate of analysis is the primary document available, and knowing how to read it matters.
Vendor evaluation checklist
- Accredited third-party COA: The certificate of analysis should be issued by a laboratory independent from the vendor, holding ISO 17025 accreditation or equivalent. The lab name, accreditation number, and direct contact information should be verifiable against the accrediting body's public registry.
- Batch-specific documentation: The COA should match the exact batch number on the product you are purchasing. Undated or unbatched COAs offer no meaningful quality assurance about what is in the specific vial or lyophilized powder you receive.
- Identity confirmation, not just purity: HPLC purity data (ideally 98% or above) tells you the relative abundance of the target molecule. It does not confirm that molecule is actually TB-500. Mass spectrometry or amino acid analysis confirming the peptide's sequence should accompany purity data.
- Absence of treatment or outcome claims: A vendor making claims about TB-500 healing injuries, treating conditions, or producing specific physiological outcomes is marketing outside the legal boundaries of a research compound. Such claims are a signal about vendor practices generally, not a feature of the product.
- Transparent business identity: Reputable research vendors operate with verifiable business addresses, visible contact information, and a clear process for batch inquiries. Anonymous or opaque operations increase quality and fraud risk.
- No human-use instructions included: Legitimate research compound vendors do not supply injection guides, reconstitution protocols, or dosing recommendations with their products, as doing so would constitute marketing for human use outside approved channels.
Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation of TB-500 or the vendor criteria above. See our full disclosure policy.
Looking for a vendor that meets these criteria?
We reviewed vendors against the checklist above, with particular attention to COA documentation and identity verification testing. The following link goes to a research vendor whose batch traceability and third-party testing documentation we found consistent with the standards described in this article. We have not evaluated the product itself, and this is not a clinical recommendation or endorsement for human use.
View vendor COA documentation Affiliate linkRelated peptides
TB-500 is frequently discussed alongside BPC-157, another research-only peptide with preclinical signals in tissue repair. The two are sometimes combined in vendor offerings. They work through different mechanisms and have distinct evidence bases.
Sources
- 1 Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. PubMed
- 2 Philp D, Badamchian M, Scheremeta B, et al. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair Regen. 2003;11(1):19-24. PubMed
- 3 Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-2151. PubMed
- 4 Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PubMed
- 5 Mannava S, et al. Thymosin beta4 is a potential regulator of hepatic stellate cells. World J Gastroenterol. 2013;19(44):7937-7942. PubMed
- 6 Chopp M, Zhang ZG. Thymosin beta4 as a restorative/regenerative therapy for neurological injury and disease. Ann N Y Acad Sci. 2012;1269:9-14. PubMed
- 7 World Anti-Doping Agency. Prohibited List 2024: S2 Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA.org
- 8 FDA. Human drug compounding: regulatory information on sections 503A and 503B. FDA.gov
